Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Inhibiting CDK6 protein prevents leukemic stem cells

Inhibiting CDK6 protein prevents leukemic stem cells

Yale researcher receives 2015 Frontiers of Knowledge Award in Biomedicine

Yale researcher receives 2015 Frontiers of Knowledge Award in Biomedicine

CHLA researchers develop new protein-based therapy against drug-resistant leukemia cells

CHLA researchers develop new protein-based therapy against drug-resistant leukemia cells

New study focuses on improving Iowa healthcare exchange

New study focuses on improving Iowa healthcare exchange

ASCO announces cancer Advance of the Year

ASCO announces cancer Advance of the Year

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Celator Pharmaceuticals' CPX-351 receives FDA Fast Track designation for secondary AML treatment

Celator Pharmaceuticals' CPX-351 receives FDA Fast Track designation for secondary AML treatment

CAR T-cell therapy enters into Phase I clinical trial

CAR T-cell therapy enters into Phase I clinical trial

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies

Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies

PF-114 shows promise in therapy-resistant CML, Ph-positive ALL

PF-114 shows promise in therapy-resistant CML, Ph-positive ALL

Enzymes linked to diabetes, obesity play major roles in arthritis and leukemia

Enzymes linked to diabetes, obesity play major roles in arthritis and leukemia

Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

Gamida Cell granted FDA and EMA orphan drug designation for NiCord

Gamida Cell granted FDA and EMA orphan drug designation for NiCord

Oncoceutics, MD Anderson partner to develop novel anti-cancer drug

Oncoceutics, MD Anderson partner to develop novel anti-cancer drug

Study shows that reprogramming stem cells can prevent cancer following full body radiation

Study shows that reprogramming stem cells can prevent cancer following full body radiation

Radiation/chemotherapy increases risk of leukemia in early-stage breast cancer patients

Radiation/chemotherapy increases risk of leukemia in early-stage breast cancer patients

Study reveals why older people are at higher risk for developing cancer

Study reveals why older people are at higher risk for developing cancer

FDA approves intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi)

FDA approves intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi)

Study reveals why older people are at increased risk for developing cancer

Study reveals why older people are at increased risk for developing cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.